TY - JOUR
T1 - Trial Watch
T2 - Dendritic cell-based interventions for cancer therapy
AU - Vacchelli, Erika
AU - Vitale, Ilio
AU - Eggermont, Alexander
AU - Fridman, Wolf Hervé
AU - Fučíková, Jitka
AU - Cremer, Isabelle
AU - Galon, Jérôme
AU - Tartour, Eric
AU - Zitvogel, Laurence
AU - Kroemer, Guido
AU - Galluzzi, Lorenzo
N1 - Funding Information:
Jitka Fucíková works for Sotio a.s. (Prague, Czech Republic), which is actively investigating DC-based vaccines in both preclinical and clinical settings. Authors are supported by the European Commission (ArtForce); European Research Council (ERC); Agence National de la Recherche (ANR); Ligue Nationale con-tre le Cancer; Fondation pour la Recherche Médicale (FRM); Institut National du Cancer (INCa); Associazione Italiana per la Ricerca sul Cancro (AIRC); Association pour la Recherche sur le Cancer (ARC), LabEx Immuno-Oncologie; Fondation de France; Fondation Bettencourt-Schueller; AXA Chair for Longevity Research; Cancéropôle Ile-de-France, Paris Alliance of Cancer Research Institutes (PACRI) and Cancer Research for Personalized Medicine (CARPEM).
PY - 2013
Y1 - 2013
N2 - Dendritic cells (DCs) occupy a privileged position at the interface between innate and adaptive immunity, orchestrating a large panel of responses to both physiological and pathological cues. In particular, whereas the presentation of antigens by immature DCs generally results in the development of immunological tolerance, mature DCs are capable of priming robust, and hence therapeutically relevant, adaptive immune responses. In line with this notion, functional defects in the DC compartment have been shown to etiologically contribute to pathological conditions including (but perhaps not limited to) infectious diseases, allergic and autoimmune disorders, graft rejection and cancer. Thus, the possibility of harnessing the elevated immunological potential of DCs for anticancer therapy has attracted considerable interest from both researchers and clinicians over the last decade. Alongside, several methods have been developed not only to isolate DCs from cancer patients, expand them, load them with tumorassociated antigens and hence generate highly immunogenic clinical grade infusion products, but also to directly target DCs in vivo. This intense experimental effort has culminated in 2010 with the approval by the US FDA of a DC-based preparation (sipuleucel-T, Provenge®) for the treatment of asymptomatic or minimally symptomatic metastatic castration-refractory prostate cancer. As an update to the latest Trial Watch dealing with this exciting field of research (October 2012), here we summarize recent advances in DC-based anticancer regimens, covering both high-impact studies that have been published during the last 13 mo and clinical trials that have been launched in the same period to assess the antineoplastic potential of this variant of cellular immunotherapy
AB - Dendritic cells (DCs) occupy a privileged position at the interface between innate and adaptive immunity, orchestrating a large panel of responses to both physiological and pathological cues. In particular, whereas the presentation of antigens by immature DCs generally results in the development of immunological tolerance, mature DCs are capable of priming robust, and hence therapeutically relevant, adaptive immune responses. In line with this notion, functional defects in the DC compartment have been shown to etiologically contribute to pathological conditions including (but perhaps not limited to) infectious diseases, allergic and autoimmune disorders, graft rejection and cancer. Thus, the possibility of harnessing the elevated immunological potential of DCs for anticancer therapy has attracted considerable interest from both researchers and clinicians over the last decade. Alongside, several methods have been developed not only to isolate DCs from cancer patients, expand them, load them with tumorassociated antigens and hence generate highly immunogenic clinical grade infusion products, but also to directly target DCs in vivo. This intense experimental effort has culminated in 2010 with the approval by the US FDA of a DC-based preparation (sipuleucel-T, Provenge®) for the treatment of asymptomatic or minimally symptomatic metastatic castration-refractory prostate cancer. As an update to the latest Trial Watch dealing with this exciting field of research (October 2012), here we summarize recent advances in DC-based anticancer regimens, covering both high-impact studies that have been published during the last 13 mo and clinical trials that have been launched in the same period to assess the antineoplastic potential of this variant of cellular immunotherapy
KW - Antigen-presenting cells
KW - Immunogenic cell death
KW - Monoclonal antibodies
KW - Plasmacytoid dendritic cells
KW - Regulatory T cells
KW - Toll-like receptors
UR - http://www.scopus.com/inward/record.url?scp=84890254287&partnerID=8YFLogxK
U2 - 10.4161/onci.25771
DO - 10.4161/onci.25771
M3 - Article
AN - SCOPUS:84878002092
SN - 2162-4011
VL - 2
JO - OncoImmunology
JF - OncoImmunology
IS - 10
M1 - e25771
ER -